D'Agostino D - Search Results

1

Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function.

Martinón-Torres F, Bernatowska E, Shcherbina A, Esposito S, Szenborn L, Marti MC, Hughes S, Faust SN, Gonzalez-Granado LI, Yu LM, D'Agostino D, Calabresi M, Toneatto D, Snape MD. Martinón-Torres F, et al. Pediatrics. 2018 Sep;142(3):e20174250. doi: 10.1542/peds.2017-4250. Epub 2018 Aug 1. Pediatrics. 2018. PMID: 30068713 Clinical Trial.

2

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.

McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Yu LM, Toneatto D, D'Agostino D, Dull PM, Pollard AJ. McQuaid F, et al. CMAJ. 2015 Apr 21;187(7):E215-E223. doi: 10.1503/cmaj.141200. Epub 2015 Mar 23. CMAJ. 2015. PMID: 25802309 Free PMC article. Clinical Trial.

3

Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.

Szenborn L, Block SL, Jackowska T, Konior R, D'Agostino D, Smolenov I, Toneatto D, Welsch JA. Szenborn L, et al. Pediatr Infect Dis J. 2018 May;37(5):475-482. doi: 10.1097/INF.0000000000001896. Pediatr Infect Dis J. 2018. PMID: 29329168 Clinical Trial.

4

A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.

Block SL, Szenborn L, Daly W, Jackowska T, D'Agostino D, Han L, Dull PM, Smolenov I. Block SL, et al. Vaccine. 2015 May 15;33(21):2500-10. doi: 10.1016/j.vaccine.2015.03.001. Epub 2015 Mar 17. Vaccine. 2015. PMID: 25795256 Clinical Trial.

5

Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine.

Nolan T, Santolaya ME, de Looze F, Marshall H, Richmond P, Henein S, Rheault P, Heaton K, Perrett KP, Garfield H, Gupta A, Ferguson M, D'Agostino D, Toneatto D, O'Ryan M. Nolan T, et al. Vaccine. 2019 Feb 21;37(9):1209-1218. doi: 10.1016/j.vaccine.2018.12.059. Epub 2019 Jan 26. Vaccine. 2019. PMID: 30691980 Free article. Clinical Trial.

6

Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers.

Bona G, Castiglia P, Zoppi G, de Martino M, Tasciotti A, D'Agostino D, Han L, Smolenov I. Bona G, et al. Vaccine. 2016 Jun 17;34(29):3363-70. doi: 10.1016/j.vaccine.2016.05.009. Epub 2016 May 12. Vaccine. 2016. PMID: 27181507 Free article. Clinical Trial.

7

Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Miethke AG, Moukarzel A, Porta G, Covarrubias Esquer J, Czubkowski P, Ordonez F, Mosca A, Aqul AA, Squires RH, Sokal E, D'Agostino D, Baumann U, D'Antiga L, Kasi N, Laborde N, Arikan C, Lin CH, Gilmour S, Mittal N, Chiou FK, Horslen SP, Huber WD, Jaecklin T, Nunes T, Lascau A, Longpre L, Mogul DB, Garner W, Vig P, Hupertz VF, Gonzalez-Peralta RP, Ekong U, Hartley J, Laverdure N, Ovchinsky N, Thompson RJ. Miethke AG, et al. Among authors: d agostino d. Lancet Gastroenterol Hepatol. 2024 May 6:S2468-1253(24)00080-3. doi: 10.1016/S2468-1253(24)00080-3. Online ahead of print. Lancet Gastroenterol Hepatol. 2024. PMID: 38723644

8

Sex differences in interacting genetic and functional connectivity biomarkers in Alzheimer's disease.

Williamson JN, James SA, Mullen SP, Sutton BP, Wszalek T, Mulyana B, Mukli P, Yabluchanskiy A; Alzheimer’s Disease Neuroimaging Initiative Consortium; Yang Y. Williamson JN, et al. Geroscience. 2024 Apr 10. doi: 10.1007/s11357-024-01151-x. Online ahead of print. Geroscience. 2024. PMID: 38598069

9

Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer's Disease Neuroimaging Initiative cohort.

Oka T, Matsuzawa Y, Tsuneyoshi M, Nakamura Y, Aoshima K, Tsugawa H; Alzheimer’s Disease Metabolomics Consortium. Oka T, et al. Sci Rep. 2024 Apr 2;14(1):6797. doi: 10.1038/s41598-024-56837-1. Sci Rep. 2024. PMID: 38565541 Free PMC article.

10

Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature.

European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN); European Association for the Study of the Liver (EASL); North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN); Latin‐American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (LASPGHAN); Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology and Nutrition (APPSPGHAN); Pan Arab Society for Pediatric Gastroenterology and Nutrition (PASPGHAN); Commonwealth Association of Paediatric Gastroenterology & Nutrition (CAPGAN); Federation of International Societies of Pediatric Hepatology, Gastroenterology and Nutrition (FISPGHAN). European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), et al. J Pediatr Gastroenterol Nutr. 2024 May;78(5):1190-1196. doi: 10.1002/jpn3.12156. Epub 2024 Mar 26. J Pediatr Gastroenterol Nutr. 2024. PMID: 38529849

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

522 results

Search Page